Scarica l'app Stockscreener
7.16
4.22%
0.29
Pre-mercato:
7.27
0.11
+1.54%
Precedente Chiudi:
$6.87
Aprire:
$6.93
Volume 24 ore:
7.96M
Relative Volume:
2.06
Capitalizzazione di mercato:
$741.63M
Reddito:
$45.97M
Utile/perdita netta:
$-508.80M
Rapporto P/E:
-1.3066
EPS:
-5.48
Flusso di cassa netto:
$-382.65M
1 W Prestazione:
-21.83%
1M Prestazione:
-19.00%
6M Prestazione:
-54.48%
1 anno Prestazione:
-66.51%
Intervallo 1D:
$6.9175
$7.59
Intervallo di 1 settimana:
$6.83
$9.785
Portata 52W:
$5.90
$28.18
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Nome
Intellia Therapeutics Inc
Settore
Industria
Telefono
857-285-6200
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Confronta NTLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
7.16 | 965.92M | 45.97M | -508.80M | -382.65M | -5.48 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-21 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-03-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Sell |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-06-16 | Iniziato | BofA Securities | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-02-18 | Iniziato | William Blair | Outperform |
| 2022-02-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Iniziato | Cowen | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
| 2021-10-05 | Iniziato | Guggenheim | Buy |
| 2021-09-24 | Iniziato | Stifel | Buy |
| 2021-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-07 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Iniziato | Truist | Buy |
| 2020-10-14 | Iniziato | Wells Fargo | Overweight |
| 2020-09-18 | Iniziato | Goldman | Buy |
| 2020-02-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-11-01 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-10 | Iniziato | ROTH Capital | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-11-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-10-29 | Iniziato | Credit Suisse | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Mkt Perform |
| 2018-05-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-11-01 | Reiterato | Jefferies | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-05 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
ARK Investment Acquires 226K Shares of Intellia Therapeutics (NT - GuruFocus
Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administration - Benzinga
ARK Investment Acquires 226K Shares of Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus
Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK buys Intellia, 10x Genomics, sells Tesla stock - Investing.com Australia
Intellia slides after safety concern for Regeneron-partnered gene editing therapy - MSN
StockWatch: Intellia Stumbles on News of Patient’s Severe Liver Toxicity - Genetic Engineering and Biotechnology News
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study - Yahoo Finance
Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip - MSN
Intellia shares tumble on safety signal in gene-editing trial - The Pharma Letter
Intellia stock dips following safety event in Phase III gene therapy trial - Clinical Trials Arena
Intellia Therapeutics (NTLA) Receives Continued 'Buy' Rating fro - GuruFocus
Intellia: Shares Sink on Safety Concern in Phase 3 Trial; Lowering Fair Value to $60 From $75 - Morningstar
ARK Investment Acquires Significant Stake in Intellia Therapeutics (NTLA) | NTLA Stock News - GuruFocus
No-Moat Intellia's Gene-Editing Pipeline Looks Promising for Long-Term, Risk-Tolerant Investors - Morningstar
Intellia Therapeutics (NTLA) Faces Challenges Amid Safety Concer - GuruFocus
Intellia adverse event could resurface questions, says JPMorgan - TipRanks
Intellia Therapeutics (NTLA) Faces Setback with Late-Stage Trial Incident - GuruFocus
Intellia: Heart Disease Safety Setback Triggers SelloffCaution Advised (NASDAQ:NTLA) - Seeking Alpha
Intellia Shares Drop 19% After Safety Signal Emerges in Phase 3 Trial - MSN
Intellia Therapeutics Shares Drop 25 Percent After Liver Stress Reported in Gene-Editing Trial - geneonline.com
Intellia tumbles on liver safety signal for CRISPR therapy - FirstWord Pharma
Intellia Therapeutics Faces Safety and Efficacy Challenges with Nex-Z: Analyst Issues Sell Rating - TipRanks
Intellia filing spurs safety concerns over CRISPR drug - BioPharma Dive
Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course - Benzinga
Intellia commercial position in question after safety event. says Goldman - TipRanks
Intellia Plunges in Latest Example of Gene Therapy Troubles - Bloomberg
Analysts Brush Off Intellia’s Adverse Event but Gene Therapy Safety Concerns Continue - BioSpace
Intellia Therapeutics (NTLA) Faces Revised Price Target Amid Study Concerns | NTLA Stock News - GuruFocus
Intellia stock holds $45 target despite AE concerns By Investing.com - Investing.com Nigeria
Intellia's stock sinks on gene therapy patient's raised enzyme levels, but analysts keep faith - Fierce Biotech
Intellia Therapeutics (NTLA) Stock Drops After Trial Update | NT - GuruFocus
H.C. Wainwright maintains $30 target on Intellia stock post-safety update - Investing.com
Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews - Benzinga
Cantor maintains Intellia stock at $65 target despite trial concern By Investing.com - Investing.com India
Intellia stock tumbles on safety concerns By Investing.com - Investing.com Canada
Intellia stock tumbles on safety concerns - Investing.com
Intellia stock down on safety concern for gene editing drug - Seeking Alpha
Wedbush Cuts Price Target on Intellia Therapeutics to $7 From $10, Keeps Neutral Rating - marketscreener.com
NTLA: Intellia Therapeutics Advances Key Clinical Trials | NTLA Stock News - GuruFocus
BofA cuts Intellia stock target to $39, maintains Buy rating By Investing.com - Investing.com India
Intellia stock holds after JMP reiterates market perform - Investing.com Australia
Intellia stock holds after JMP reiterates market perform By Investing.com - Investing.com India
Intellia Therapeutics: Buy Rating Affirmed Despite Safety Concerns in MAGNITUDE Study - TipRanks
Intellia reports progress in Phase 3 clinical trials - Investing.com
Intellia Therapeutics Updates on Phase 3 Study Progress - TipRanks
Intellia Therapeutics announces two-year follow-up data from trial of nex-z - MSN
Intellia Therapeutics’s SWOT analysis: gene editing pioneer’s stock faces pivotal phase - Investing.com
Analysts Think These Stocks Could More Than Double in Value - Investing.com
Analysts Think These Stocks Could More Than Double in Value - MarketBeat
INTELLIA ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):